Jacob Francis, Nixdorf Sheri, Hacker Neville F, Heinzelmann-Schwarz Viola A
Ovarian Cancer Group, Adult Cancer Program, Lowy Cancer Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia ; Department of Biomedicine, Gynecological Research Group, University Hospital Basel, University of Basel, Basel, Switzerland.
Ovarian Cancer Group, Adult Cancer Program, Lowy Cancer Centre, Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
J Ovarian Res. 2014 Jun 7;7:60. doi: 10.1186/1757-2215-7-60. eCollection 2014.
Ovarian cancer is the fifth most common cause of cancer death in women and the leading cause of death from gynaecological malignancies. Of the 75% women diagnosed with locally advanced or disseminated disease, only 30% will survive five years following treatment. This poor prognosis is due to the following reasons: limited understanding of the tumor origin, unclear initiating events and early developmental stages of ovarian cancer, lack of reliable ovarian cancer-specific biomarkers, and drug resistance in advanced cases. In the past, in vitro studies using cell line models have been an invaluable tool for basic, discovery-driven cancer research. However, numerous issues including misidentification and cross-contamination of cell lines have hindered research efforts. In this study we examined all ovarian cancer cell lines available from cell banks. Hereby, we identified inconsistencies in the reporting, difficulties in the identification of cell origin or clinical data of the donor patients, restricted ethnic and histological type representation, and a lack of tubal and peritoneal cancer cell lines. We recommend that all cell lines should be distributed via official cell banks only with strict guidelines regarding the minimal available information required to improve the quality of ovarian cancer research in future.
卵巢癌是女性癌症死亡的第五大常见原因，也是妇科恶性肿瘤死亡的主要原因。在被诊断为局部晚期或播散性疾病的女性中，只有30%的人在治疗后能存活五年。这种不良预后归因于以下原因：对肿瘤起源的了解有限、卵巢癌起始事件和早期发育阶段不明确、缺乏可靠的卵巢癌特异性生物标志物以及晚期病例中的耐药性。过去，使用细胞系模型的体外研究一直是基础的、探索性癌症研究的宝贵工具。然而，包括细胞系错误识别和交叉污染在内的诸多问题阻碍了研究工作。在本研究中，我们检查了细胞库中所有可用的卵巢癌细胞系。据此，我们发现了报告中的不一致之处、细胞起源或供体患者临床数据识别方面的困难、种族和组织学类型代表性受限以及缺乏输卵管和腹膜癌细胞系的情况。我们建议所有细胞系应仅通过官方细胞库分发，并制定严格的指导方针，规定所需的最少可用信息，以提高未来卵巢癌研究的质量。
